A meta-analysis of the effect of coronary artery collaterals on percutaneous coronary intervention (PCI) in acute ST-segment elevation myocardial infarction (STEMI) in a previous of Angiology analyzed 14 observational studies (10 411 patients). 1 In this article, Cui et al report significant benefit of coronary artery collateral blood flow (CCBF) for reduction in mortality at 6 months and short-term 30-day mortality. 1 On the other hand, no significant differences were found in risk of recurrent myocardial infarction (MI) or need for target lesion revascularization following PCI in these patients with acute MI. 1 Trying to explain these findings has uncovered some interesting studies.
Collateral Circulation Characteristics and Genetics
The recognized value of CCBF is as a blood supply for ischemic myocardium. Obstructive coronary artery disease (CAD) results in enlargement of collaterals, even with already significant native CCBF. 2 The apparent protective benefit of native and stimulated CCBF is improvement in both cardiac and all-cause mortality in relation to acute and chronic CAD and in decreasing major adverse cardiac events (MACEs). 2 However, it should be noted that in the study by Cui et al, there was no benefit in MACE reported. 1 Additional protection may also come from exercise training, which has significant general benefit for the patient with CAD and may also increase the development of CCBF. 3 Alternatively, coronary ectasia in the presence of significant CAD is associated with decreased CCBF. 4 Remote ischemic preconditioning (RIC) has been evaluated as adjunct therapy in patients with STEMI managed with PCI. 5 A typical protocol for RIC is 20 minutes ischemia by inflation of an arm blood pressure cuff to 200 mm Hg, followed by reperfusion, with a reported decrease in myocardial endothelial dysfunction with cardiac ischemia. 6 The presence of CCBF involving the STEMI-related artery benefited patients undergoing RIC in addition to PCI as measured by myocardial salvage index (MSI). This finding was further confirmed in a meta-analysis as well as a reduction in MACE. 7 However, more research is essential before a change in practice recommendations can be made. Genetic studies suggest racial and ethnic differences in CCBF. Hispanics were found to have higher CCBF than African Americans and non-Hispanic whites (59%, 50%, and 48%, respectively, P ¼ .017). In this same study of 868 patients with obstructive CAD evaluated for CCBF, increased CCBF was found to be associated with a region on chromosome 17 in Native Americans and with a different region on the same chromosome in African Americans. 8 Sex differences may also exist; however, studies are not conclusive. One study of 450 patients, approximately 75% of whom were male, found no sex differences in CCBF. 9 Another study involving 463 patients that investigated significance of diabetes mellitus (DM) in CCBF found that men with DM younger than 55 years had greater development of coronary collaterals than similarly aged women with DM. 10 However, older women with DM and hypertension developed similar collaterals to older men with DM. These studies are small and have enrolled low numbers of women. As many women with both ischemia and infarction have nonobstructive CAD at angiography, it can be hypothesized that women develop fewer coronary collaterals than men. Women are also known to have a higher prevalence of angina and a worse prognosis. 11, 12 Understanding the mechanisms leading to sex differences in CCBF may explain the variations in presentations and outcomes.
Vasculogenesis
The role of vasculogenesis (both angiogenesis and arteriogenesis) warrants discussion when considering how to increase CCBF. Angiogenesis results from hypoxia and involves formation of new capillaries, whereas arteriogenesis involves remodeling of preexisting arterioarteriolar anastomoses with induction by physical forces, especially fluid shear stress. 13 The extensive preexisting CCBF network in human hearts has been well established for over 50 years.
14 The CCBF vessels enlarge with closure of an epicardial coronary artery. Circulating cells, especially monocytes, penetrate proliferating vessel walls, and secrete growth factors involved in CCBF. An intracoronary artery derivation of coronary collateral flow index can evaluate vasculogenic response to trial medications and compounds.
14 The so-called therapeutic angiogenesis by delivery to the heart of angiogenic growth factors for the development of revascularization and CCBF has been tested but is not in latestage clinical trials. 15, 16 Clinical trial evidence supports that in patients with CAD, vasculogenesis has potential for development of CCBF, with benefit for the ischemic heart from various growth factors and transplanted bone marrow-derived angioblasts. 17 A nicotinamide adenine dinucleotide phosphate oxidase may be important for early compensatory CCBF through various intermediates and ultimate dependence on generation of hydrogen peroxide. 18 As already mentioned, increased microRNA (miRNA) appears to be associated with decreased CCBF; plasma miRNA may represent a possible marker for decreased CCBF. Increased miRNA appears to be negatively correlated with vascular cell adhesion protein 1 in the presence of decreased CCBF. 19 
Chronic Total Occlusion of Coronary Arteries
Revascularization of coronary artery chronic total occlusion (CTO) has become a goal of PCI due to technology that makes it possible to treat anatomically complex lesions. 20 Registries have been established to follow the progress of CTO revascularization with concern that these procedures will become fully accepted prior to adequate proof of benefit in well-designed trials and establishing standard indications, equipment, training, and safety. 20, 21 The CCBF can satisfy resting metabolic cardiac requirements but not under stress in spite of the degree of CCBF evaluated by arteriography and physiologic assessment. 22 A 2015 review found that successful retrograde passage of a wire through collateral channels in appropriate patients could result in revascularization of complex CTO with a low risk of major complications. 23 The importance of CCBF would appear key in planning PCI and in anticipated benefit. The role of CCBF in the prognosis of patients after MI remains disputed. To date, 12 studies have investigated the effect of CCBF on survival, but only 3 have demonstrated any clinical benefit. 24 Why the discrepancy? On the one hand, the number and diameter of angiographically detectable CCBF increases with duration of acute coronary occlusion 25 ; this developing recruitment is associated with myocardial recovery and improved left ventricular function. In essence, the presence of CCBF during acute ischemia is a critical factor for the protection of myocardial viability. Analogous to bypass grafting, collaterals can be regarded as an organic bypass system. This explains why a recent metaanalysis of about 6500 patients in 12 studies noted a mortality benefit for CCBF in an unselected population of patients with ischemic heart disease. 26 On the other hand, a study conducted in 330 patients with STEMI found no relationship between coronary collaterals (assessed with the angiographic Rentrop scale) and improved long-term clinical outcomes in patients after STEMI treated with primary PCI. 27 This is not illogical, since CCBF needs ischemia to become more robust and time of ischemia has been shortened by PCI. Furthermore, this may result from the negative correlation between the Rentrop score and antegrade flow in the infarct-related artery (the better the collaterals, the worse the antegrade flow).
A caveat regarding coronary collaterals is that in spite of benefit for STEMI survival, the risk of restenosis following PCI has been reported to be increased with good collaterals compared to poor collaterals. 24 In a meta-analysis, there was an increased occurrence of restenosis for all PCI with good collaterals when compared to poor collaterals (risk ratio [RR] 1.64, 95% confidence interval [CI], 1.14-2.35). 24 In the same meta-analysis, the occurrence of restenosis was less with STEMI (RR 1.23, 95% CI, 0.89-1.69). 24 In a study of 216 patients with stable angina with drug-eluting stent PCI performed for CTO, good CCBF (Rentrop 2-3) was more frequently associated with right coronary CTO, whereas poor CCBF (Rentrop 0-1) was more frequent in CTO of the left anterior descending. 28 In this same study, DM and CTO vessel diameter were independent risk factors for in-stent restenosis, whereas Rentrop grade for CCBF was not associated with instent restenosis (odds ratio 0.795, 95% CI, 0.365-1.732, P ¼ .414). 28 Existence of collaterals would overall appear beneficial, but such a meta-analysis and other study results on restenosis add confusion. For example, a meta-analysis of CCBF in patients with CAD from 12 studies involving 6529 patients found that increased CCBF was associated with a 36% decreased mortality risk versus low CCBF. 26 For stable patients with CAD, increased CCBF resulted in decreased mortality (RR 0.59, 95% CI, 0.39-0.89, P ¼ .012); however, for acute STEMI, the result was similar but not significant (RR 0.63, 95% CI, 0.29-1.39, P ¼ .257). 26 Given the conflicting data, more studies are needed, and the meta-analysis in this issue of Angiology has several important limitations. Study heterogeneity is a problem that can arise when attempting to compare different populations and end points. Unless the individual results of included studies are consistent, it is difficult to determine the generalizability of findings. The studies incorporated in this meta-analysis are varied in terms of clinical and angiographic characteristics as well as outcomes. 1 For example, as noted by the authors, the studies used different Rentrop classifications to define collaterals. Although patient characteristics were fairly similar in terms of age, male preponderance, and the presence of hypertension, there were discrepancies in terms of DM, active smoking, and, importantly, in multivessel disease, cardiogenic shock, and infarct-related artery. Furthermore, the presenting chest pain duration was also discrepant, ranging from <6 to 24 hours. Certain end points have particularly divergent and limited data. This is evidenced by the Forest plot on target vessel revascularization, which incorporates only 2 studies with very few events combined. The correlation between preprocedural CCBF levels and long-term outcome may be attributable to type 1 error, as all CIs are very wide.
To account for the heterogeneity, the authors conducted subgroup analysis, pooled analysis of multivariable-adjusted or propensity matched data exclusively, and meta-regression analysis; they concluded that different clinical characteristics had an insignificant effect on their results. 1 An advantage of this meta-analysis is that it included >10 000 patients. 1 Most previous studies on the effects of CCBF for patients with acute MI were modest; evaluating hard clinical end points requires thousands of patients and long-lasting follow-up.
Conclusions
The subject of CCBF is not simple and straightforward. In the meta-analysis of Cui et al, CCBF was associated with reduction in 6 months and short-term 30-day mortality but not in recurrent MI or target lesion revascularization. 1 The occurrence of CCBF is variable. Techniques such as RIC may contribute to CCBF formation and increase MSI. Inconsistencies include observations such as the association of right coronary CTO with good CCBF (Rentrop 2-3) and CTO of the left anterior descending more associated with poor CCBF (Rentrop 0-1). 28 Genetics play a role in CCBF with sex, racial, and ethnic differences noted. Vasculogenesis appears to play a role in the formation of collaterals, but clinical trials are not yet available to support the use of vasculogenic growth factors. Backup circulation for CAD in the form of CCBF certainly appears desirable, but how to use and improve it in clinical and interventional cardiology remains to be defined.
